PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31805962-0	2019	Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.	saracatinib	43-54	AKT serine/threonine kinase 1	Homo sapiens	36-39	
31805962-10	2019	Cathepsin B-sensitive NPs for co-delivering saracatinib and capivasertib significantly improved the efficacy of tumor repression without increasing side effects, which were due to highly specific tumor-targeting drug delivery system and synergistic anticancer effects by co-inactivation of AKT and Src in HNSCC cells.	saracatinib	44-55	AKT serine/threonine kinase 1	Homo sapiens	290-293	
24492292-5	2014	Our data demonstrated that trastuzumab plus saracatinib was much more potent than either agent alone in reducing the phosphorylation of ErbB3 and AKT in both NCI-N87 and NCI-N87R gastric cancer cell lines.	saracatinib	44-55	AKT serine/threonine kinase 1	Homo sapiens	146-149	
29550144-0	2018	miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.	saracatinib	66-77	AKT serine/threonine kinase 1	Homo sapiens	108-111	
19240653-7	2009	AZD0530 gave a potent and sustained blockage of AKT and enhanced the sensitivity to irradiation.	saracatinib	0-7	AKT serine/threonine kinase 1	Homo sapiens	48-51	
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	saracatinib	33-44	AKT serine/threonine kinase 1	Homo sapiens	83-86	
22450814-6	2012	These effects by saracatinib were not accompanied by the expected decline of Src family kinases but were accompanied by Akt-mammalian target of rapamycin suppression and/or mediated via another pathway.	saracatinib	17-28	AKT serine/threonine kinase 1	Homo sapiens	120-123	
19451593-10	2009	AZD0530-resistant tumors showed activation of bypass pathways including MEK and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin, raising the possibility that MEK, mammalian target of rapamycin (mTOR), or PI3K inhibitors may augment Src inhibitor efficacy.	saracatinib	0-7	AKT serine/threonine kinase 1	Homo sapiens	117-120	
34158343-6	2021	Additionally, AZD0530 was shown to inhibit the radiation-induced EGFR/PI3K/AKT pathway which in known to promote and regulate radioresistance and survival of GBM cells by radiation.	saracatinib	14-21	AKT serine/threonine kinase 1	Homo sapiens	75-78